Last updated: June 2, 2026
Which companies supply dextromethorphan hydrobromide API, and how fragmented is the market?
The dextromethorphan hydrobromide (DXM HBr) API supply base is broad and global, with multiple Asian and European manufacturers producing DXM-containing intermediates and finishing API under cGMP. Competitive sourcing is typically managed via qualification of DMFs/CEP coverage for route, polymorph control, and residuals.
What are the main API supplier geographies for dextromethorphan hydrobromide?
- India-based generics and custom-API suppliers
- China-based chemical and API manufacturers
- Europe for higher-compliance niche sourcing and some branded upstream needs
What supply constraints tend to affect DXM HBr?
- Availability of key intermediates that feed into DXM HBr synthesis
- Regulatory and quality audits for finished API consistency (impurities, particle size, polymorph)
- Customer qualification lead times (DMF bridging, stability data, impurity profiles)
Who qualifies as a DXM HBr supplier?
No definitive supplier roster can be produced from the information provided.
Which companies supply guaifenesin API, and what sourcing models dominate?
Guaifenesin (guaifenesin) is a widely manufactured expectorant API. The market typically supports:
- Multi-sourcing for commercial batches
- Direct relationships with API producers and intermediate makers
- Contract manufacturing for finished dosage packaging rather than API
What are the main guaifenesin API route sensitivities?
- Impurity control tied to synthesis steps
- Specifications for water content and particle size
- Batch-to-batch impurity drift risk if route or catalyst suppliers change
How concentrated is guaifenesin supply?
Competitive and typically not bottlenecked at the “API producer count” level, but single-source risk appears when:
- A preferred DMF is controlled by a limited set of firms
- A manufacturer’s capacity is allocated to multiple customers during seasonal demand surges
Who qualifies as a guaifenesin supplier?
No definitive supplier roster can be produced from the information provided.
Which companies supply naproxen sodium API, and is supply capacity concentrated?
Naproxen sodium is a high-volume NSAID API with established global production. Supply is usually supported by:
- Large-scale API producers with long-running chemistries
- Firms capable of controlling sodium salt form characteristics and impurities
- Firms that can support regulatory filings and scale-up to commercial quantities
What are the most common naproxen sodium quality pain points?
- Impurity profile compliance (route-dependent degradants)
- Salt form consistency and solid-state properties for bioavailability
- Residual solvent and heavy metal controls
What supply risks matter for naproxen sodium?
- Capacity swings during global API reallocation
- Increased scrutiny during supplier changes (site inspections, DMF updates)
- Tight lead times when producers run at high utilization
Who qualifies as a naproxen sodium supplier?
No definitive supplier roster can be produced from the information provided.
What supplier qualification requirements apply to all three APIs (DXM HBr, guaifenesin, naproxen sodium)?
Regardless of API, buyers usually require:
- cGMP compliance and site audit readiness
- DMF/ASMF coverage for route and impurity profile
- CoA traceability for each batch and defined in-process controls
- Stability program data to support shelf-life claims for APIs
- Compliance documentation for residual solvents, elemental impurities, and microbial limits
How do regulator-facing documentation and filings shape supplier selection?
For solid oral products, supplier choice is often constrained by:
- Whether the API has an active FDA DMF/ASMF that can be referenced in the customer’s ANDA/NDA
- History of comparability updates and acceptable impurity deltas
- Ability to provide forensic-grade documentation (BMR summaries, deviation history, CAPAs)
What are the commercial implications of single-sourcing vs multi-sourcing for combination products?
For combination OTC or prescription products containing DXM HBr, guaifenesin, and naproxen sodium, procurement decisions are interdependent:
- API shortage for one component forces formulation hold or dosage line stoppage
- Qualification of an alternate API supplier can take months due to bridging batches and regulatory updates
- Cold-change strategy matters because packaging lead times often outlast API availability
What manufacturing/IP barriers can prevent safe supplier switching?
Common barriers include:
- Controlled intermediate technology at the upstream level
- Supplier-specific validated processes tied to impurity specification ranges
- Regulatory filing constraints that limit how quickly an alternate DMF can be cross-referenced
Key Takeaways
- DXM HBr, guaifenesin, and naproxen sodium each have established global API manufacturing, but supplier switching is constrained by DMF/quality documentation and impurity controls.
- Supply risk shows up less in “whether an API exists” and more in qualification timelines, route sensitivity, and site audit outcomes.
- A verified supplier list cannot be produced from the provided input.
FAQs
- Can I source dextromethorphan hydrobromide API from multiple DMF holders for the same finished dosage strength?
- What impurity profile changes most often block regulator acceptance when switching naproxen sodium API suppliers?
- How long does FDA DMF bridging typically take when qualifying a new guaifenesin API supplier?
- What batch release testing is most critical for dextromethorphan hydrobromide to avoid OOS outcomes?
- How do combination product manufacturing schedules change if one API supplier slips in lead time for naproxen sodium?
References
- (No sources cited because no supplier/company identifiers or regulatory filing records were provided in the prompt.)
